Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISION Phase 3 trial of lutetium Lu 177 vipivotide tetraxetan in PSMA-positive metastatic castration-resistant prostate cancer
NL-OMON52710Phase 3Active, not recruiting
- Sponsor
- Endocyte
- Start
- Dec 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa) (2 arms), sponsored by Endocyte. Primary endpoints: Overall survival and Radiographic progression-free survival. Started Dec 2018; status: active, not recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON52710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52710.